Sage Journals: Discover world-class research

Abstract

B-cell lymphomas are composed of tumor cells and the tumor microenvironment, which is conventionally thought to be composed of a mixture of stromal cells, blood vessels, immune cells, and non-cell components, such as extracellular matrix, cytokines, and chemokines. Exosomes, small endocytically derived vesicles that have been proved to be present in a variety of tumor niches and involved in mediating cell signaling networks, are increasingly regarded as important components of tumor microenvironment. In this review, we first focus on the biogenesis, biodistribution, transportation, and other general characteristics of exosomes and then highlight the vital roles of exosomes in lymphomagenesis and disease progression, particularly from the perspective of immune dysfunction, virus infection, and therapeutic resistance mechanisms.

Keywords

Microenvironment exosomes B-cell lymphomas lymphomagenesis drug resistance immunotherapy

Introduction

Lymphomas are a group of malignant tumors of lymphoid tissues.¹ The World Health Organization (WHO) classification,¹ published in 2016, has categorized lymphomas into more than 80 distinct entities, principally on the basis of morphology, immunophenotype, genetic alterations, and clinical features. Among them, B-cell lymphomas are characterized by arising from malignant transformations of B-lymphoid cells, including Hodgkin’s lymphomas and most of non-Hodgkin lymphomas. The highly complex process of lymphomagenesis and tumor progression may involve chromosomal abnormalities and gene mutations, as well as the dynamic interaction between the tumor cells and the tumor microenvironment (TME), which has profound influence on cell behaviors physiologically and pathologically.^2,3

The TME of B-cell lymphomas mainly contains variable numbers of mesenchymal stem cells, stromal cells, immune cells, and, but not limited to, soluble factors.^4,5 The complex interplay between tumor cells and TME regulates tumorigenesis and provides novel targets for immunotherapies. One of the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints, such as the antibodies of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programed cell death-1 (PD-1).⁶ According to 56th annual meeting of the American Society of Hematology, Phase-I clinical trials have confirmed the activity and safety of nivolumab⁷ and pembrolizumab⁸ (both drugs are monoclonal antibodies that bind to and inhibit PD-1) in patients with lymphomas. The mechanism of immune checkpoint inhibitors (ICIs) for tumor therapy is to re-activate antitumor immune system by blocking inhibitory immune checkpoint molecules or their ligands, which are often overexpressed on immune cells of TME and tumor-cell surfaces.^9,10 PD-1 is often overexpressed on surfaces of T cells in TME, leading to suppression of T-cell proliferation and function and interferon gamma (IFN-γ) and interleukin-2 (IL-2) production.⁹ Nivolumab, an IgG4-κ immunoglobulin of about 146 kDa that binds to PD-1, promotes CTL proliferation and resistance to Treg-mediated suppression and consequently reverse T-cell exhaustion.^11,12 Despite clinical successes to date, the exact mechanisms of ICIs are not fully understood.

Recently, it has been increasingly noticed that the potential functions of extracellular vesicles, such as microvesicles (MVs) and exosomes, contributed to various aspects of tumorigenesis,^13,14 particularly with a focus on the exosome-mediated cell signaling. The cancer cell–released exosomes mediate cell–cell interactions and the communications between neoplastic cells and non-cell elements, which may also play a fundamental role in building an organization of the TME.¹⁵ Exosomes affect tumor development and progression mainly by altering the phenotype of receiver cells via diverse exosomal cargoes including proteins, DNA, messenger RNAs (mRNAs), and microRNAs.¹⁶

This review will summarize recent advances on the fundamental understanding of exosomes and the TME of B-cell lymphomas and uncover the interaction between them based on published experimental evidences.

Exosomes’ biogenesis, biodistribution, and transportation

Exosomes, a group of typical microparticles (30–100 nm in size) secreted by different cells, are first reported by Pan and Johnstone¹⁶ in 1983 as unwanted cellular components extruding from reticulocytes. Nowadays, exosomes are recognized as the natural carriers of many signal molecules that mediate cell–cell communication and exert critical influences on tumorigenesis,¹⁷ autoimmune diseases,¹⁸ infections,^19,20 and cardiovascular diseases.^21,22

The biogenesis of exosomes starts with the formation of late endosomes, also called multivesicular bodies (MVBs), which originate from reverse invagination of the cellular plasma membrane. Exosomes are released from cells into adjacent microenvironment when the peripheral membrane of MVBs fuses with the cellular plasma membrane.²³ Mazzeo et al.²⁴ showed that protein kinase D1/2 participated in this complex process, including the maturation of MVBs and the secretion of exosomes in T and B lymphocytes. A wide variety of cells are capable of releasing exosomes, including mesenchymal stem cells (MSCs),²⁵ dendritic cells (DCs),²⁶ B cells,^27,28 T cells,^29,30 natural killer (NK) cells,³¹ and particularly tumor cells.³² Thus, apart from blood, lymph, and cerebrospinal fluid, exosomes are also present in various other body fluids including urine, synovial fluid, breast milk, saliva, amniotic fluid, and malignant effusions of ascites. Once released, exosomes can spread through body fluids to affect functions of the recipient cells.³³ B-cell lymphomas can involve almost any lymphoid tissue in the body, including lymph nodes and different organs and occasionally involving bone and causing osteolytic lesions.³⁴ It is more likely to spread to distant parts of the body partly because the lymphatic system is composed of a network of interconnecting lymph nodes and lymphatic vessels that assist tumor cells to spread distantly. Peinado et al.³⁵ reported that exosome production, biodistribution, transportation, and subsequent function of educating bone marrow progenitor cells assist melanoma growth and metastasis. We assume that exosomes derived from lymphoma cells also participate in the lymphoma dissemination, but the detailed mechanism needs to be further studied. The exact mechanism of how exosomes communicate with target cells is not yet clear. Based on in vitro studies, it is proposed that exosomes might mediate distant intercellular communication through membrane fusion,³⁶ endocytosis,³⁷ or receptor-mediated internalization.^38–40 In addition, accumulating evidence points out a new mechanism that exosomes burst and release their contents to regulate the recipient cells, similar to a paracrine mechanism.⁴¹

Composition and cargo

Exosomes are generally composed of two parts, the bilayer lipid membrane and the intra-vesicular content that is closely related to the reverse invagination of the plasma membrane.⁴² These nanoscale membrane vesicles have powerful effects in regulating physiological as well as pathological processes in extracellular milieu and rely on intra-vesicular cargoes, including mRNAs, microRNAs, proteins, lipids, and signaling molecules. Recent research showed that the presence of single- and double-stranded DNA molecules also can be detected in tumor-derived exosomes.^43,44 Dong et al.⁴⁵ reported larger quantity of long noncoding RNAs (lncRNAs) in the exosomes from colorectal cancer serum than that in other membrane vesicles, including apoptotic bodies and MVs. Most contents enriched in exosomes are molecules with the same orientation as that of the producer cells, while a small set of cellular components is selectively enriched, including endosome-associated proteins (e.g. Alix), proteins that associated with lipid raft (flotillin and glycosylphosphatidylinositol-anchored protein), and tetraspanins (e.g. CD63, CD9, CD81, and CD82).^17,46 Although these markers play crucial roles in purification and identification of exosomes, these classically used exosome markers are not unique to exosomes, whereas they are similarly present in all EVs.³⁷ As a result of their endosomal origin, exosomes generally do not contain mitochondria, endoplasmic reticulum, or nuclear proteins.⁴⁷ The illustration of biogenesis and composition of exosome and the possible communication mechanism between exosomes and target cells are shown in Figure 1.

Figure 1.

Biogenesis and composition of exosome, and the possible communication mechanism between exosomes and target cells. Biogenesis of exosomes begins with the formation of late endosomes, also called multivesicular bodies (MVBs), which originate from reverse invagination of the cellular plasma membrane. Exosomes are released from cells into adjacent microenvironment when the peripheral membrane of MVBs fuses with the cellular plasma membrane. Exosomes are composed of two parts, the bilayer lipid membrane and the intra-vesicular content, including mRNAs, microRNAs, DNA, proteins, lipids, and signaling molecules. Some proteins enriched in exosomes are selectively enriched, termed as exosomal markers, including Alix, flotillin, CD63, CD9, CD81, and CD82. The secreted exosomes act in autocrine or paracine to exhibit their effects with cells. It is proposed that exosomes might mediate distant intercellular communication though membrane fusion, endocytosis, or receptor-mediated internalization.

Biological functions in tumorigenesis

Exosomes seem to be a novel and powerful intercellular signal mediator between cancer cells and its microenvironment. The functions of these nanosized vesicles appear to rely on its cargoes and surface biomolecules. Multiple studies indicate that exosomes are actually involved in different phases of carcinogenesis and tumor development.^48–55

From the perspective of tumor-initiating property, Melo et al.¹⁷ demonstrated that the non-tumorigenic MCF10A cells formed tumor mass in nude mice when co-injected with cancer cell–derived exosomes, and Dicer blocking in these exosomes could reduce tumor formation. This oncogenic conversion of MCF10A cells attributes to precursor microRNAs (pre-miRNAs), along with Dicer, AGO2 (Argonaute2), and TRBP (HIV-1 TAR RNA binding protein) in exosomes of cancer cells. The functional microRNAs within exosomes are associated with the RNA-induced silencing complex (RISC)-loading complex (RLC) that display capacity of processing pre-miRNAs to mature microRNAs in a cell-independent manner. Moreover, Boelens et al.⁴⁸ showed that RNAs within stromal cell-derived exosomes stimulated STAT1 and NOTCH3 signaling in breast cancer cells and disseminated tumor cells through promoting stem cell population, which is blamed for the initiation of tumor formation and therapy resistance.

In addition to acting as an initiator of carcinogenesis, cancer cell–derived exosomes also can promote tumor-cell dissemination and metastasis via distinct cargo molecules. Pre-metastatic niches usually have been formed in the receptor organs before tumor-cell metastasis and in which exosomes might be involved. Costa-Silva et al.⁴⁹ reported that pancreatic ductal adenocarcinomas–secreted exosomes induced pre-metastatic niche formation due to the exosomal cargo macrophage migration inhibitory factor (MIF). Besides, their subsequent study found that a variety of tumor-derived exosomes uptaken by organ-specific recipient cells also established a favorable microenvironment that promoted the colonization and growth of disseminated tumor cells upon their arrival.⁵⁰ Proteomics uncovered that distinct integrin expression patterns contributed to tumor metastasis, for example, the exosomal integrins α6β4 and α6β1 for lung metastasis and exosomal integrin αvβ5 for liver metastasis. They also reported that exosomal integrin uptaken by recipient cells induced expression of several metastasis-related genes, including pro-inflammatory S100. In the respect of tumor metastasis, Zhou et al.⁵¹ showed that breast cancer–derived exosomes destroyed vascular endothelial barrier to facilitate metastasis by targeting the tight junction protein ZO-1 via exosomal miR-105. Zhang et al.⁵² revealed the role of exosomal cargo in tumor metastasis by conducting the following PTEN experiment. PTEN loss could promote the tumor-cell dissemination in the brain since PTEN is an important tumor suppressor. Intriguingly, the PTEN level in PTEN-loss brain metastatic tumor cells was restored once leaving the brain microenvironment. This brain microenvironment-dependent, reversible PTEN mRNA and protein downregulation were epigenetically mediated by the microRNAs in brain astrocyte-derived exosomes. Thus, depletion of PTEN-targeting microRNAs in astrocytes or inhibition of astrocyte-derived exosome secretion could rescue the PTEN loss and simultaneously suppress brain metastasis. A report showed the result of a reproducibility project: melanoma exosomes facilitated bone marrow progenitor cells transforming into a pro-metastatic phenotype via MET protein, an oncogenic receptor tyrosine kinase that is frequently aberrantly activated in tumors.⁵³ Besides above studies, Syn et al.⁵⁴ have elaborated exosome-mediated metastasis in their study.

In addition to the above-mentioned pathological and physiology functions, exosomes can be applied as effective tumor markers. Melo et al.⁵⁵ showed that the surface of pancreatic cancer exosomes was rich in glypican-1 (GPC1), and GPC1⁺ exosomes could be detected in the serum of patients with pancreatic cancer with absolute specificity and sensitivity, therefore distinguishing between patients with a benign pancreatic disease and early- or late-stage pancreatic cancer. Their study revealed that the levels of GPC1⁺ circulating exosomes were related to tumor burden and the survival of pre- and post-surgical patients.

Collectively, these studies indicate that the evil little things, cancer-derived exosomes, could promote tumor metastasis and the formation of pre-metastatic niches and may also serve as a potential non-invasive diagnostic marker for the development of tumor. Since few exosome-related studies have been performed on lymphoma, we will discuss recent reports that suggested exosomes play a peculiar role in B-cell lymphomagenesis in the following sections.

Role of the components in the lymphoma microenvironment

B-cell lymphomas consist of a wide range of entities and consequently have various clinical behaviors, causing significant morbidity and mortality worldwide. While substantial proportion of studies indicated that genetic alterations can give rise to lymphomagenesis, like many other malignancies, increasing evidences also revealed that the TME has crucial impact on lymphoma initiation and progression.⁵ The special structures of bone marrow and lymphoid organs, including lymph nodes and the spleen, make the TME of lymphomas significantly different from that of other hematological malignancies or solid tumors. In addition to malignant cells, the TME of B-cell lymphomas is composed of a mixture of stromal cells (fibroblastic reticular cells and mesenchymal stem/stromal cells), blood vessels, immune cells (T- and B-cells, macrophages, dendritic cells, and antigen-presenting cells), and non-cell components, such as extracellular matrix, cytokines, and chemokines. Notably, infectious agents are involved in microenvironmental abnormalities that might result in lymphomas. In return, lymphomas bring changes to the microenvironment.

Mesenchymal stem/stromal cells (MSCs) represent one of the central cellular components of the lymphoma microenvironment⁵⁶ and play an important role in the regulation of tumor engraftment, proliferation, and vessel density⁵⁷ as well as drug resistance.⁵⁸ It is also believed that macrophages are present virtually in any tumor niche, while within the B-cell lymphomas they are named tumor-associated macrophages (TAMs) or lymphoma-associated macrophages (LAM). Both MSCs and LAM contribute significantly to the progression of lymphoma. MSCs induced lymphoma progression mainly by enhancing the growth of transplanted tumors through elevating the expression of CC Chemokine Receptor 2 (CCR2) ligands (e.g. CCL-2, CCL-7, and CCL-12) to facilitate recruiting macrophages/monocytes toward the tumor sites.⁵⁹ Recently, a novel mechanism showed by Lin et al.⁶⁰ have uncovered that MSCs recruited macrophages to the tumor sites via CCR2 chemotaxis axis and subsequently facilitated tumor growth in melanoma and lymphoma under the help of tumor cell–derived exosomes. Therefore, MSCs and LAM, even the tiny particles such as exosomes, might be the potential therapeutic targets for reducing tumor burden.

The intratumoral T-cells, a heterogeneous group of immune cells that are subdivided into various subpopulations including CD8⁺ T cells, regulatory T cells (Treg), helper T cells (Th), and follicular helper T cells (TFH), account for up to 50% of the intratumoral cells demonstrated by tumor biopsies from those patients diagnosed with B-cell lymphomas.⁶¹ The role of T-cell subpopulations in lymphoma progression is obviously complex, which produce great effects not only on immunosuppression^62–64 but also on activation of antitumor immune responses.⁶⁵

Besides, data obtained from immunotherapies also give affirmation to NK cells in the functions of anti-lymphoma.⁶⁶ Natural killer group 2D (NKG2D), a germline-encoded receptor, plays an important role in NK-mediated immunosurveillance, while it is not only expressed on NK cells but also on activated CD8⁺ T cells, natural killer T (NKT) cells, and certain CD4⁺ T cells. NKG2D is an activating surface molecule that recognizes stress-inducible self-molecules, including major histocompatibility complex (MHC)-related ligands. NKG2D is poorly expressed in healthy cells but significantly upregulated in malignant cells.⁶⁷ The overexpression of NKG2D in tumor cells induced the upregulation of NKG2D ligands (NKG2D-L) leading to a higher sensitivity of NKG2D-dependent NK-mediated cell killing.⁶⁸ The study on Eµ-Myc mouse models found an NKG2D-L upregulation at early stages of lymphomagenesis, uncovered a mechanism for oncogenic transformation.⁶⁹ It is believed that the downregulation of NKG2D-L on circulating immune cells suppresses the NKG2D-dependent pathway of cytotoxicity,^70,71 thus it could be identified as a mechanism of tumor escape. Moreover, Salih et al.⁷⁰ indicated that NKG2D-L-expressing tumor cells evaded the immunosurveillance through matrix metalloprotease cleavage of the ligands from cell surface into a soluble form. Recently, plenty of studies showed a novel mechanism for NKG2D/NKG2DL-dependent pathway in immune escape with a focus on tumor-cell exosomes.^72–75

Lymphoma exosomes participate in antitumor effect and immune dysfunction

Understanding how exosomes interact with the immune system in B-cell lymphomas is significantly important for the development of immunotherapeutic strategies. Tumor cell–derived exosomes, which have been reported to contain tumor antigens and MHC class I molecules, can present tumor antigens to dendritic cells and induce CD8⁺ T-cell-dependent antitumor immune responses, leading to direct suppression of malignant tumor development.^76,77 Back in the 1990s, Raposo et al.⁷⁸ have shown that the exosome-mediated fusion between MHC class II and the plasma membrane was the new pathway for antigen presentation. In the study of lymphomas, Chen et al.⁷⁹ showed that exosomes released from heat-shocked mouse B lymphoma cells (HS-Exo) contain heat shock proteins (HSP) and numerous amounts of molecules involved in immunogenicity, including MHC class I, MHC class II, CD40, CD86, RANTES, and IL-1β. Furthermore, HS-Exo could activate T-cell responses more potently and induce significantly increased antitumor immune responses in prophylaxis and therapeutic in vivo lymphoma models. In conclusion, exosomes from particular cells provide innovative approaches for tumor immunotherapy due to their immunogenicity.

However, tumor cell–derived exosomes are also crucial in conferring intercellular signals to regulate the evasion from immunosurveillance and immunosuppression in the TME during the disease progression.^79,80 Exosomes participate in immunoregulation through proteins on cell surface and the intra-vesicular content. Tumor-derived vesicles were proved to induce immune cell apoptosis through the receptor-mediated pathway.^81,82 For instance, previous evidence pointed toward Fas ligand (FasL)-positive microvesicles as the mediator of inhibiting immune responses by inducing T-cell apoptosis.^83,84 Recently, Ahmed et al.⁸⁵ showed that Epstein–Barr virus (EBV), implicated in several types of lymphomas, could hijack the exosomes to induce apoptosis in a large number of cell types, including T-cells, B-cells, and epithelial cells, possibly led to T-cell depression.

In addition to inducing immune cell apoptosis, another way of exosomes assisting cancer cell to escape the immunosurveillance is reducing the antigen presentation. NK-cell activities are regulated by the interplay of activating and inhibitory receptors.⁸⁶ NKG2D has been shown as an important component of the immune network in B-cell lymphomas, and NKG2D/NKG2DL-mediated system in cancer cells are well-documented.^73,75,87 Hedlund et al.⁸⁸ used lymphoma cell line Raji as a model for the studies of NKG2D receptor-ligand system in B-cell lymphomas. They found that NKG2DL-bearing lymphoma exosomes suppressed the NKG2D receptor–mediated cytotoxicity, thus impaired NK-cell function. This study suggested that tumor evasion of immune surveillance was regulated by the shedding of exosomes, which affect the cytotoxic ability of NK cells by the active antigen molecules. The new mechanism might somewhat provide an explanation of the high rate of immune dysfunction in patients with relapsed lymphomas. In Figure 2, we have shown that lymphoma-derived exosomes transfer cargoes to the surrounding cells leading to immune dysfunction.

Figure 2.

Elucidation of the B-cell lymphoma-derived exosome-mediated transformation of the tumor microenvironment. Lymphoma-derived exosomes transfer varied cargoes to the surrounding stromal, endothelial, immune, and lymphoma cells leading to immune dysfunction, stromal cell phenotype transformation, angiogenesis, and therapeutic resistance.

Exosomes participate in multiple kinds of immune-escape mechanisms by which cancer cell evasion takes control over the immune system. Among a variety of complex immune mechanisms, apoptosis induction and impaired antigen presentation have been reported in B-cell lymphomas. Other immune regulations of exosomes, like gene regulatory effects⁸⁹ and secretion of immunosuppressive factors,⁹⁰ are reported in lung cancer and breast cancer, respectively.

Potential roles of exosomes in virus-related lymphomas

Multiple evidences have established the theory that viral agents, including EBV, the Kaposi’s sarcoma-associated herpesvirus (KSHV), and human immunodeficiency virus type 1 (HIV-1), are considered fully responsible for the development of lymphoid malignancies, especially in the initiation of B-cell lymphomas.

Three pathomechanisms implicated in this malignant transformation process have been identified:⁹¹ first, direct tumorigenesis action, such as lymphocyte infection and transformation directly induced by EBV and KSHV; second, inflammatory stimulation, some virus, like hepatitis C virus (HCV), stimulates chronic B-cell activation and inflammation by producing viral antigenic and soluble factors; and third, immunodeficiency, as particularly caused by HIV-1, which facilitates depletion of Th and Tregs, thereby leading to immunosuppression and the initiation of malignant neoplasm.

While the majority of published researches on viral-associated lymphomas were focused on the direct transforming abilities of viral products in tumor cells, there is increasing evidence that the indirect actions (i.e. immunosuppression, neovasculature, and TME components) of different viruses also play significant roles in lymphomagenesis.³ As oncogenic properties, multiple viral agents participate in microenvironmental abnormalities through a wide set of viral genes and their encoded oncoproteins, including HIV-1 p24, EBV EBNAs, LMPs, BARF, KSHV vFLIP, and LANAs.^92,93 Besides the well-known HIV-1 capacity of causing the depletion of CD4⁺ T cells, there are other virus-driven immunodeficiency mechanisms impacting the immune TME. For example, EBV and HIV-1 are proved capable of inducing the overexpression of PD-L1 on antigen-presenting cells, thus resulting in immunosuppression by the increased apoptosis of T cells. Furthermore, macrophages are also involved in viral-associated immunity dysfunction, since the tissue macrophages represent a reservoir of HIV-1, and HIV-positive macrophages have been shown with lymphomagenic potential in severe combined immunodeficiency (SCID) mice.⁹⁴ In addition, Liapis et al.⁹⁵ found that the microvessel density in AIDS-related lymphomas was probably associated with EBV latent membrane protein 1 (LMP1) signaling and revealed a mechanism of virus-induced angiogenesis, showing that virus-infected endothelial cells modified the TME.

Recent studies indicated that KSHV, EBV, and possibly other viruses can manipulate the TME through the secretion of specific exosomes, small endocytically derived vesicles that contains peculiar viral and cellular components. Viral exosomes contain high levels of viral genetic materials, like microRNAs, and oncogenic proteins that both activate crucial signaling pathways in recipient cells.⁹⁶ The human gamma herpesviruses KSHV is associated with primary effusion lymphoma (PEL) and several other lymphoid malignancies.^97,98 Chugh et al.⁹⁹ reported that exosomes derived from patients with KSHV-associated malignancies and KSHV mouse models contained KSHV-encoded microRNAs such as miR-17-92 cluster, which is relevant in numerous signaling pathways that are identified to be critical in KSHV pathogenesis. Moreover, they discovered that exosomal virus-encoded microRNAs contributed to increased cell migration and IL-6 secretion in endothelial cells. Recently, another similar study with a focus on EBV, a virus associated with heterogeneous lymphomas, found that EBV-positive Burkitt’s lymphoma cells Raji released exosomes with miR-155 inducing angiogenesis in remote recipient cells, whereas no major difference was found in co-culture with EBV-negative Burkitt’s lymphoma cells.¹⁰⁰ Thus, it would be reasonable to believe that specific viral exosomal microRNAs contribute to angiogenesis of vascular endothelial cells, subsequently leading to pathophysiologic angiogenesis. Further research is obviously necessary in order to identify whether such nanoparticles within the TME can lead to angiogenesis even carcinogenesis in vivo.

The B-cell stimulatory capacities of exosomes released by EBV-infected lymphoma cells include the production of the activation-induced cytidine deaminase (AID), the expression of circle and germline transcripts for IgG1, and the promotion of a differentiation shift toward plasmablast-like phenotype. The viral LMP1 is proved to contribute to lymphomagenesis, although other viral proteins and cellular factors within the exosomes may also participate in these processes.¹⁰¹ Early studies suggested that LMP1 was capable of increasing the expression of a variety of proteins, including cytoskeletal proteins,¹⁰² adhesion molecules,¹⁰³ and fascin¹⁰⁴ which were relevant with the invasive migration of EBV-transformed cells.¹⁰³ In addition to LMP1 protein, EBV exosomes also contain mRNAs encoding LMP1, LMP2, EBNA1 (Epstein–Barr nuclear antigen 1), and EBNA2 (Epstein–Barr nuclear antigen 2),¹⁰⁵ but the functions of these exosomal mRNAs remain unknown. It is assumed that these exosomal mRNAs probably can be translated into oncogenic proteins in the host recipient cells. Notably, EBV-infected cells released exosomes that contain EBV specifically encoded microRNAs, and these exosomal microRNAs could induce monocyte/macrophage transforming into the tumor-associated macrophage (TAM), which showed correlation with disease outcome. Kotani¹⁰⁶ found that EBV⁺ lymphoma cells were embedded in non-neoplastic bystanders, such as B and T cells and macrophages, and interestingly, the lymphoma cells were unable to be engrafted in immunodeficient mice without these bystander cells. Their study conclusively showed the reason turned out to be that exosomal microRNAs from EBV⁺ lymphoma cells are capable of redirecting bystander cells into the tumor-supportive niche. The researchers treated monocyte/macrophage with exosomes secreted from EBV⁺ lymphoma cells, and thereafter, monocyte/macrophage was transferred into tumor-associated macrophages (TAM), due to CD69, IL-10, and tumor necrosis factor (TNF) which were induced by exosomal EBV-microRNAs.

Recent study involving immune dysfunction indicated that EBV-infected exosomes could induce apoptosis in several different kinds of cells, including T-cells through the Fas-ligand-mediated pathway, leading to the suppression of T-cell signaling.⁸⁵ Baglio et al.¹⁰⁷ showed that virus-modified exosomes also have a physiological role in the establishment of a life-long asymptomatic latent infection. Viral exosome–mediated immunity dysfunction has also been reported in other disorders recently.¹⁰⁸

Collectively, these studies indicated that the lymphoma microenvironment is altered in viral infection conditions, at least leading to angiogenesis, phenotype transformation, and immune dysfunction partly via the secretion of microRNAs and proteins carried by exosomes (Figure 2).

Exosomes as communicators of drug resistance in lymphoma

Drug resistance remains a major obstacle in implementing therapies to achieve successful outcomes against tumor. Recent study showed that exosomes removal might be an adjuvant therapy for malignancies due to the vital roles of these cell-derived microparticles in therapeutic resistance.¹⁰⁹ The intuitive mechanisms of drug resistance involving exosomes might be the sequestration of cytotoxic drugs in the intracellular microvesicles and the subsequent expulsion, to wipe out drug effect within the cells.¹¹⁰ The results of Luciani et al.¹¹¹ are in accord with the above conclusion and demonstrated that lymphoma, adenocarcinoma, and melanoma cells confiscated drugs such as vinblastin, 5-flurouracil, and cisplatin in their endosomal compartments. Further studies revealed that high levels of adenosine triphosphate (ATP)-binding cassette (ABC) transporter A3 (ABCA3) were related to drug resistance,^112,113 especially by drug expulsion which might be modulated by microparticles.¹¹⁴

As for targeting therapy of B-cell lymphoma exosomes, Aung et al.¹¹⁵ supported this mechanism by showing that exosomes, carrying CD20 and lysosome-related organelle-associated ABCA3, released from B-cell lymphoma, bound to therapeutic anti-CD20 antibody and consumed complement, thereby impairing antibody-dependent cell-mediated cytotoxicity (ADCC) and protecting cancer cells from antibody attack. Besides, they also mentioned that more than one-third plasma rituximab bound to exosomes in patients treated with therapeutic antibody for B-cell lymphoma. Additionally, removing exosomes from plasma samples resulted in considerable improvements in the effect of rituximab against lymphoma cell lines and against autologous cancer cells in vitro. In addition to lymphoma, Ciravolo et al.¹¹⁶ also showed that the human epidermal growth factor receptor 2 (HER2)-positive exosomes released by breast cancer cells markedly attenuated the cross-talk between cancer cells and the humanized antibody trastuzumab, leading to tumor aggressiveness and therapeutic interference.

Recently, another study by Oksvold et al.¹¹⁷ has shown a similar observation that B-cell lymphoma-derived exosomes, isolated by magnetic beads, were capable to reduce rituximab-induced complement-dependent cytotoxicity. Taken together, these studies revealed a novel mechanism of drug resistance in lymphoma, which is linked to an ABCA3-dependent pathway of exosome secretion (Figure 2).

The complex interplay between lymphoma cell–derived exosomes and the TME provides target for therapeutic strategies. Targeting cancer exosomes for metastatic cancer treatment proved to be one of the therapeutic methods with great promise.¹¹⁸ Researchers recently reported that depletion of ABCA3 either via using short hairpin RNA (shRNA) or by applying the cyclooxygenase inhibitor indomethacin significantly diminished exosome secretion and increased drug susceptibility.¹¹⁹ These studies potentially facilitate new strategies to overcome drug resistance.

Summary and prospect

The malignant progression of lymphoma is complicated, and initially, the major mechanisms of B-cell lymphomagenesis were focused on the aberrations in primary tumor cells, while nowadays there is a growing recognition concentrated on the role of the TME, a complex community of stromal cells, blood vessels, immune cells, and some non-cell components. In contrast to conventional cytotoxic chemotherapy, emerging immunotherapy is a treatment that mediates patients’ own immune system to trigger antitumor response and has less toxicity. However, TME tends to be the main limitative factor preventing the sensitization and infiltration of effector T cells, thus suppressing antitumor immune response. Therefore, deeper understanding of the interaction between lymphoma cells and TME may help define new treatments or preventive tools. This review has presented a conceptual framework of the lymphoma microenvironment, contributing to cell biology, cell signaling, immunology, and treatment resistance, but not limited to aforementioned aspects. The once-underappreciated components of the microenvironment have been reviewed from numerous publications. Moreover, increasing evidences have placed a spotlight on the role of exosomes in the TME of B-cell lymphomas, especially from perspectives of mediating immune dysfunction, virus infection, and drug resistance. A profound understanding of multifunctional exosomes in the microenvironment will help to illustrate the mechanisms of lymphomagenesis and pave the way for lymphoma diagnosis and targeted therapy.

Although tissue biopsy has been identified as standard diagnostic procedure for tumor diagnosis, there are limitations in tissue biopsy–based procedures, especially for early-stage detection or when biopsy is not easily accessible. In recent years, liquid biopsy exerts a huge fascination on a great many scholars and becomes a prominent research topic in precision medicine for varied cancers. In addition to circulating tumor cells (CTC) as well as circulating DNA (ctDNA) and circulating RNA (ctRNA), circulating exosomes from different body fluid samples have been recognized as potential biomarkers because they deliver enriched cargoes, such as mRNAs, microRNAs, lncRNA, and proteins, which are well protected from nucleases and proteases by the bilayer lipid membrane of exosomes. Although a number of pioneer studies reported some biomarkers in other different diseases,^120,121 exosomal biomarkers of lymphomas and their clinical values are waiting for investigation in the near future. Beyond this, the isolation methods of exosomes, which might impact the overall study, are far from perfect and cannot be used widespread. Thus, it is necessary to develop a rapid and efficient purification method to gain high quality, high purity, and large-scale exosomes instead of mixed extracellular vesicle populations. We should cherish the hope that we will be amply rewarded in tumor therapy if the aforementioned tasks have been solved in the coming future.

Footnotes

Acknowledgements

B.X. and T.W. have contributed equally to this work.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors wish to thank National Natural Science Foundation of China (Grant No. 81570177) that supported our study.

References

Swerdlow

Campo

Pileri

. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375–2390.

Basso

Dalla-Favera

. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 2015; 15: 172–184.

Scott

Gascoyne

. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14: 517–534.

Taylor

Gribben

. Microenvironment abnormalities and lymphomagenesis: immunological aspects. Semin Cancer Biol 2015; 34: 36–45.

Shain

Dalton

Tao

. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015; 34(36): 4673–4682.

Pardoll

. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

Lesokhin

Ansell

Armand

. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1b study. J Clin Oncol 2016; 34(23): 2698–2704.

Moskowitz

Ribrag

Michot

. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study (KEYNOTE-013). Blood 2014; 124(21): 290.

Buchbinder

Desai

. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39(1): 98–106.

10.

Ribas

. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366(26): 2517–2519.

11.

Guo

Zhang

Chen

. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 2017; 8(3): 410–416.

12.

Chaudhary

Elkord

. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines 2016; 4(3): 28.

13.

Wang

Gilkes

Takano

. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 2014; 111: E3234–E3242.

14.

You

Cao

Shao

. Clinical and biological significance of HAX-1 overexpression in nasopharyngeal carcinoma. Oncotarget 2016; 7: 12505–12524.

15.

Webber

Yeung

Clayton

. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol 2015; 40: 27–34.

16.

Pan

Johnstone

. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983; 33: 967–978.

17.

Melo

Sugimoto

O’Connell

. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014; 26: 707–721.

18.

Turpin

Truchetet

Faustin

. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev 2016; 15: 174–183.

19.

Liu

. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nat Immunol 2013; 14: 793–803.

20.

Marti

Johnson

. Emerging roles for extracellular vesicles in parasitic infections. Curr Opin Microbiol 2016; 32: 66–70.

21.

Zhao

Zheng

Zhao

. Exosome and its roles in cardiovascular diseases. Heart Fail Rev 2015; 20: 337–348.

22.

Ibrahim

Marban

. Exosomes: fundamental biology and roles in cardiovascular physiology. Annu Rev Physiol 2016; 78: 67–83.

23.

Johnstone

Adam

Hammond

. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987; 262: 9412–9420.

24.

Mazzeo

Calvo

Alonso

. Protein kinase D1/2 is involved in the maturation of multivesicular bodies and secretion of exosomes in T and B lymphocytes. Cell Death Differ 2016; 23: 99–109.

25.

Bruno

Grange

Deregibus

. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20: 1053–1067.

26.

Thery

Duban

Segura

. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156–1162.

27.

Muntasell

Berger

Roche

. T cell-induced secretion of MHC class II–peptide complexes on B cell exosomes. EMBO J 2007; 26: 4263–4272.

28.

Klinker

Lizzio

Reed

. Human B cell-derived lymphoblastoid cell lines constitutively produce Fas ligand and secrete MHCII(+)FasL(+) killer exosomes. Front Immunol 2014; 5: 144.

29.

Blanchard

Lankar

Faure

. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol 2002; 168: 3235–3241.

30.

Okoye

Coomes

Pelly

. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 2014; 41: 89–103.

31.

Lugini

Cecchetti

Huber

. Immune surveillance properties of human NK cell-derived exosomes. J Immunol 2012; 189: 2833–2842.

32.

Nilsson

Skog

Nordstrand

. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603–1607.

33.

Tang

Sun

Huang

. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget 2015; 6: 44179–44190.

34.

Michigami

Nomizu

Yamada

. Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide. Clin Exp Metastasis 1998; 16(7): 645–654.

35.

Peinado

Alečković

Lavotshkin

. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18(6): 883–891.

36.

Mulcahy

Pink

Carter

. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 2014; 3: 24641.

37.

Zhang

. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics 2015; 13: 17–24.

38.

Villarroya-Beltri

Baixauli

Gutierrez-Vazquez

. Sorting it out: regulation of exosome loading. Semin Cancer Biol 2014; 28: 3–13.

39.

Munich

Sobo-Vujanovic

Buchser

. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1: 1074–1083.

40.

Raimondo

Saieva

Corrado

. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal 2015; 13: 8.

41.

Taraboletti

D’Ascenzo

Giusti

. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 2006; 8: 96–103.

42.

Robbins

Morelli

. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014; 14: 195–208.

43.

Falcone

Felsani

D’Agnano

. Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res 2015; 34: 32.

44.

Eldh

Ekstrom

Valadi

. Exosomes communicate protective messages during oxidative stress: possible role of exosomal shuttle RNA. PLoS ONE 2010; 5: e15353.

45.

Dong

Lin

. Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2016; 25: 1158–1166.

46.

Kowal

Tkach

Thery

. Biogenesis and secretion of exosomes. Curr Opin Cell Biol 2014; 29: 116–125.

47.

Schorey

Bhatnagar

. Exosome function: from tumor immunology to pathogen biology. Traffic 2008; 9: 871–881.

48.

Boelens

Nabet

. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014; 159: 499–513.

49.

Costa-Silva

Aiello

Ocean

. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015; 17: 816–826.

50.

Hoshino

Costa-Silva

Shen

. Tumour exosome integrins determine organotropic metastasis. Nature 2015; 527: 329–335.

51.

Zhou

Fong

Min

. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014; 25: 501–515.

52.

Zhang

Yao

. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 2015; 527: 100–104.

53.

Lesnik

Antes

Kim

. Registered report: melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Elife 2016; 5: e07383.

54.

Syn

Wang

Sethi

. Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci 2016; 37: 606–617.

55.

Melo

Luecke

Kahlert

. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015; 523: 177–182.

56.

Ame-Thomas

Maby-El

Monvoisin

. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007; 109: 693–702.

57.

Roorda

Elst

Boer

. Mesenchymal stem cells contribute to tumor cell proliferation by direct cell-cell contact interactions. Cancer Invest 2010; 28: 526–534.

58.

Celegato

Borghese

Casagrande

. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood 2015; 126: 1394–1397.

59.

Ren

Liu

Zhao

. Tumor resident mesenchymal stromal cells endow naive stromal cells with tumor-promoting properties. Oncogene 2014; 33: 4016–4020.

60.

Lin

Cao

. Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities. Oncogene 2016; 35: 6038–6042.

61.

Rimsza

Roberts

Miller

. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251–4258.

62.

Rawal

Chu

Zhang

. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013; 190: 6681–6693.

63.

Ame-Thomas

Hoeller

Artchounin

. CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. Blood 2015; 125: 2381–2385.

64.

Greaves

Clear

Owen

. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 2013; 122: 2856–2863.

65.

Chang

Huang

Jones

. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13: 6666–6672.

66.

Rosario

Liu

Kong

. The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res 2016; 22: 596–608.

67.

Marcus

Gowen

Thompson

. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 2014; 122: 91–128.

68.

Nausch

Cerwenka

. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944–5958.

69.

Unni

Bondar

Medzhitov

. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A 2008; 105: 1686–1691.

70.

Salih

Holdenrieder

Steinle

. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13: 3448–3456.

71.

Gonzalez

Groh

Spies

. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121–138.

72.

Clayton

Tabi

. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005; 34: 206–213.

73.

Clayton

Mitchell

Court

. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180: 7249–7258.

74.

Mincheva-Nilsson

Nagaeva

Chen

. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 2006; 176: 3585–3592.

75.

Hedlund

Stenqvist

Nagaeva

. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009; 183: 340–351.

76.

Greening

Gopal

. Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol 2015; 40: 72–81.

77.

Hao

Bai

. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 2007; 120: 90–102.

78.

Raposo

Nijman

Stoorvogel

. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183(3): 1161–1172.

79.

Chen

Wang

Shao

. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 2006; 36: 1598–1607.

80.

Bobrie

Colombo

Raposo

. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011; 12: 1659–1668.

81.

Taylor

Gerçel-Taylor

Lyons

. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9(14): 5113–5119.

82.

Wieckowski

Visus

Szajnik

. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009; 183(6): 3720–3730.

83.

Huber

Fais

Iero

. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005; 128: 1796–1804.

84.

Andreola

Rivoltini

Castelli

. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002; 195: 1303–1316.

85.

Ahmed

Philip

Attoub

. Epstein-Barr virus-infected cells release Fas ligand in exosomal fractions and induce apoptosis in recipient cells via the extrinsic pathway. J Gen Virol 2015; 96: 3646–3659.

86.

Czernek

Düchler

. Functions of cancer-derived extracellular vesicles in immunosuppression. Arch Immunol Ther Exp. Epub ahead of print 18 January 2017. DOI: 10.1007/s00005-016-0453-3.

87.

Jamieson

Diefenbach

McMahon

. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17: 19–29.

88.

Hedlund

Nagaeva

Kargl

. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE 2011; 6: e16899.

89.

Wang

Zhu

. Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signaling pathway. J Hematol Oncol 2016; 9(1): 1–12.

90.

Rong

. Immunosuppression of breast cancer cells mediated by transforming growth factor-β in exosomes from cancer cells. Oncol Lett 2016; 11(1): 500–504.

91.

Carbone

Vaccher

Gloghini

. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol 2014; 11: 223–238.

92.

Castillo

Reagan

Bishop

. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol 2014; 165: 300–315.

93.

Boshoff

. Unraveling virus-induced lymphomagenesis. J Clin Invest 2011; 121: 838–841.

94.

Zenger

Abbey

Weinstein

. Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas. Cancer Res 2002; 62: 5536–5542.

95.

Liapis

Clear

Owen

. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 2013; 122: 424–433.

96.

Meckes

Gunawardena

Dekroon

. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A 2013; 110: E2925–E2933.

97.

Schulz

Cesarman

. Kaposi’s sarcoma-associated herpesvirus: mechanisms of oncogenesis. Curr Opin Virol 2015; 14: 116–128.

98.

Wen

Damania

. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010; 289: 140–150.

99.

Chugh

Sin

Ozgur

. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog 2013; 9: e1003484.

100.

Yoon

Kim

Park

. Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt’s lymphoma exosomes. Tumour Biol 2016; 37: 313–321.

101.

Gutzeit

Nagy

Gentile

. Exosomes derived from Burkitt’s lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J Immunol 2014; 192: 5852–5862.

102.

Wang

Liebowitz

Wang

. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988; 62: 4173–4184.

103.

Dawson

Forero-Vargas

. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010; 20: 339–345.

104.

Mohr

Kalmer

Gross

. The tumor marker Fascin is induced by the Epstein-Barr virus-encoded oncoprotein LMP1 via NF-κΒ in lymphocytes and contributes to their invasive migration. Cell Commun Signal 2014; 12: 46.

105.

Canitano

Venturi

Borghi

. Exosomes released in vitro from Epstein-Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Lett 2013; 337: 193–199.

106.

Kotani

. Role of tumor-derived secretary small RNAs in EBV related lymphoma. Uirusu 2014; 64: 43–48.

107.

Baglio

van Eijndhoven

Koppers-Lalic

. Sensing of latent EBV infection through exosomal transfer of 5’pppRNA. Proc Natl Acad Sci U S A 2016; 113: E587–E596.

108.

Yang

Han

Hou

. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. Epub ahead of print 30 May 2016. DOI: 10.1038/cmi.2016.24.

109.

Marleau

Chen

Joyce

. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10: 134.

110.

Shedden

Xie

Chandaroy

. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 2003; 63: 4331–4337.

111.

Luciani

Spada

De Milito

. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702–1713.

112.

Chapuy

Koch

Radunski

. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008; 22: 1576–1586.

113.

Steinbach

Gillet

Sauerbrey

. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006; 12: 4357–4363.

114.

Chapuy

Panse

Radunski

. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 2009; 94: 1528–1536.

115.

Aung

Chapuy

Vogel

. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A 2011; 108: 15336–15341.

116.

Ciravolo

Huber

Ghedini

. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2011; 227(2): 658–667.

117.

Oksvold

Kullmann

Forfang

. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther 2014; 36: 847–862.e1.

118.

Takahashi

Prietovila

Hironaka

. The role of extracellular vesicle microRNAs in cancer biology. Clin Chem Lab Med 2017; 55: 648–656.

119.

Koch

Aung

Vogel

. Nuclear trapping through inhibition of exosomal export by indomethacin increases cytostatic efficacy of doxorubicin and pixantrone. Clin Cancer Res 2016; 22: 395–404.

120.

Thompson

Gray

Heman-Ackah

. Extracellular vesicles in neurodegenerative disease-pathogenesis to biomarkers. Nat Rev Neurol 2016; 12: 346–357.

121.

Qin

. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles 2015; 4: 27522.

Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes

Abstract

Keywords

Introduction

Exosomes’ biogenesis, biodistribution, and transportation

Composition and cargo

Biological functions in tumorigenesis

Role of the components in the lymphoma microenvironment

Lymphoma exosomes participate in antitumor effect and immune dysfunction

Potential roles of exosomes in virus-related lymphomas

Exosomes as communicators of drug resistance in lymphoma

Summary and prospect

Footnotes

Acknowledgements

Declaration of conflicting interests

Funding

References